Clinical trial
Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
NCT00329381 · University of Mississippi Medical Center, Other · Completed
Key facts
| NCT number | NCT00329381 |
|---|---|
| Title | Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy |
| Official title | A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab)on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids |
| Lead sponsor | University of Mississippi Medical Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Xolair |
| Enrollment | 14 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | May 24, 2006 |
| Last update posted | Jun 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: